Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 371 clinical trials
Optimal Timing of BR55 CEUS of the Ovaries

This is an exploratory, single center, open label, prospective study of BR55 to determine the optimal phase of the menstrual cycle for performing BR55 CEUS of the target ovary in premenopausal women scheduled to undergo preventative surgery because of high familial/hereditary or genetic risk for ovarian cancer.

cancer
congestive heart failure
hysterectomy
systemic therapy
hypertension
  • 0 views
  • 16 Feb, 2024
  • 1 location
Full Metall Jacket Multilevel Segment

The lack of damage to the skin avoids complications in the postoperative and remote periods of observation, thereby improving the quality of life

  • 0 views
  • 16 Feb, 2024
  • 1 location
Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells Transplantation in Patients With Type 2 Diabetes Mellitus

The trial includes a 3-week early screening and lifestyle education period, 6-week treatment period, and 18-week follow-up period. Chinese type 2 diabetic subjects receiving traditional hypoglycemic treatment were randomly assigned to umbilical cord mesenchymal stem cell or placebo infusion therapy to observe the efficacy and safety of umbilical cord mesenchymal …

body mass index
antidiabetic agent
hypoglycemic agents
antidiabetic agents
  • 0 views
  • 16 Feb, 2024
  • 1 location
Durvalumab (MEDI4736) Plus Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal Cancer

Patients will receive durvalumab 1500 mg every 4 weeks during induction chemotherapy, chemoradiotherapy and waiting period until surgery.

mrt3
serum bilirubin
adjuvant therapy
mfolfox-6
diarrhea
  • 0 views
  • 16 Feb, 2024
  • 10 locations
Open-label Flexible-dose Study of Vortioxetine in Patients With Depression in India

The purpose of this study is to evaluate the safety and tolerability of flexible doses of vortioxetine (5 - 20 mg/day) over a period of 12 weeks in patients with depression in India

depressive disorder
major depressive disorder, single episode
depression
vortioxetine
depressive episode
  • 0 views
  • 16 Feb, 2024
  • 8 locations
Transcranial Static Magnetic Field Stimulation (tSMS) in Amyotrophic Lateral Sclerosis (ALS).

Clinical status will be tested before, during and after the stimulation period. Moreover, cortical excitability will be tested by transcranial magnetic stimulation (TMS) before and after the stimulation period.

excitability
amyotrophic lateral sclerosis
epilepsy
percutaneous endoscopic gastrostomy
antidepressants
  • 0 views
  • 16 Feb, 2024
  • 2 locations
Ketorolac as an Adjuvant Agent for Postoperative Pain Control Following Arthroscopic Meniscus Surgery

In light of the rising opioid epidemic and nationwide initiatives to limit narcotic usage, surgeons must explore alternate pain modalities in the acute postoperative period. Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) with analgesic and anti-inflammatory properties.1 Multiple prior studies have examined the beneficial effect of oral and intravenous (IV) …

analgesia
postoperative pain
drugs of abuse
narcotics
drug abuse
  • 0 views
  • 16 Feb, 2024
  • 1 location
Fourth Trimester - A Web-based Tool for Postpartum Care to Address the Needs of Underserved Women

The postpartum period is a critical time for both maternal and child health, and more than half of all maternal deaths occur postpartum, from one day to one year after birth.

  • 0 views
  • 05 Aug, 2020
A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fed)  

This was an open-label, randomized, fed, single-dose, 2-sequence, 2- period crossover study to evaluate the pharmacokinetics and safety between single oral administration of "BR3006" and co-administration of "BR3006A", "BR3006B," and "BR3006C" in healthy adult volunteers.

Accepts healthy volunteers
  • 0 views
  • 05 Nov, 2025
  • 1 location
IPG7236 in Patients With Advanced Solid Tumors

The study will include a dose escalation phase (Part 1) and a dose expansion phase (Part 2). Each part will consist of a screening period of up to 28 days, a treatment period, an end of treatment visit and a safety follow-up of approximately 30 days after the last dose.

  • 0 views
  • 03 Dec, 2021
  • 1 location